AUSTIN, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that yesterday it received correspondence from Pfizer, Inc. (NYSE:PFE).
This correspondence is available at: http://investor.paintrials.com/sec.cfm .
The company furnished the correspondence with the Securities and Exchange Commission pursuant to the submission of a Current Report on Form 8-K.About Pain Therapeutics, Inc. Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. The FDA has not approved any of our drug candidates for commercial sale. For more information, please visit www.paintrials.com .
CONTACT: For More Information Contact: Peter S. Roddy Vice President and Chief Financial Officer Pain Therapeutics, Inc. email@example.com (512) 501-2450
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts